{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,22]],"date-time":"2026-10-22T05:42:50Z","timestamp":1792647770254,"version":"4.5.0"},"reference-count":62,"publisher":"Springer Science and Business Media LLC","issue":"11","license":[{"start":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T00:00:00Z","timestamp":1479168000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T00:00:00Z","timestamp":1479168000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Transl Psychiatry"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Alzheimer\u2019s disease (AD) is the most common cause of dementia. Biomarkers are required to identify individuals in the preclinical phase, explain phenotypic diversity, measure progression and estimate prognosis. The development of assays to validate candidate biomarkers is costly and time-consuming. Targeted proteomics is an attractive means of quantifying novel proteins in cerebrospinal and other fluids, and has potential to help overcome this bottleneck in biomarker development. We used a previously validated multiplexed 10-min, targeted proteomic assay to assess 54 candidate cerebrospinal fluid (CSF) biomarkers in two independent cohorts comprising individuals with neurodegenerative dementias and healthy controls. Individuals were classified as \u2018AD\u2019 or \u2018non-AD\u2019 on the basis of their CSF T-tau and amyloid A\u03b21\u201342 profile measured using enzyme-linked immunosorbent assay; biomarkers of interest were compared using univariate and multivariate analyses. In all, 35\/31 individuals in Cohort 1 and 46\/36 in Cohort 2 fulfilled criteria for AD\/non-AD profile CSF, respectively. After adjustment for multiple comparisons, five proteins were elevated significantly in AD CSF compared with non-AD CSF in both cohorts: malate dehydrogenase; total APOE; chitinase-3-like protein 1 (YKL-40); osteopontin and cystatin C. In an independent multivariate orthogonal projection to latent structures discriminant analysis (OPLS-DA), these proteins were also identified as major contributors to the separation between AD and non-AD in both cohorts. Independent of CSF A\u03b21\u201342 and tau, a combination of these biomarkers differentiated AD and non-AD with an area under curve (AUC)=0.88. This targeted proteomic multiple reaction monitoring (MRM)-based assay can simultaneously and rapidly measure multiple candidate CSF biomarkers. Applying this technique to AD we demonstrate differences in proteins involved in glucose metabolism and neuroinflammation that collectively have potential clinical diagnostic utility.<\/jats:p>","DOI":"10.1038\/tp.2016.194","type":"journal-article","created":{"date-parts":[[2016,11,15]],"date-time":"2016-11-15T13:45:35Z","timestamp":1479217535000},"page":"e952-e952","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":67,"title":["A targeted proteomic multiplex CSF assay identifies increased malate dehydrogenase and other neurodegenerative biomarkers in individuals with Alzheimer\u2019s disease pathology"],"prefix":"10.1038","volume":"6","author":[{"given":"R W","family":"Paterson","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"W E","family":"Heywood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A J","family":"Heslegrave","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N K","family":"Magdalinou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"U","family":"Andreasson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Sirka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E","family":"Bliss","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"C F","family":"Slattery","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Toombs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J","family":"Svensson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"P","family":"Johansson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N C","family":"Fox","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H","family":"Zetterberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K","family":"Mills","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J M","family":"Schott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,11,15]]},"reference":[{"key":"BFtp2016194_CR1","doi-asserted-by":"publisher","first-page":"332","DOI":"10.1016\/j.jalz.2015.02.003","volume":"11","author":"Alzheimer\u2019s Association","year":"2015","unstructured":"Alzheimer\u2019s Association. 2015 Alzheimer\u2019s disease facts and figures. Alzheimers Dement 2015; 11: 332.","journal-title":"Alzheimers Dement"},{"key":"BFtp2016194_CR2","doi-asserted-by":"publisher","first-page":"614","DOI":"10.1016\/S1474-4422(14)70090-0","volume":"13","author":"B Dubois","year":"2014","unstructured":"Dubois B, Feldman HH, Jacova C, Hampel H, Molinuevo JL, Blennow K et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol 2014; 13: 614\u2013629.","journal-title":"Lancet Neurol"},{"key":"BFtp2016194_CR3","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/S1474-4422(12)70291-0","volume":"12","author":"CR Jack Jr.","year":"2013","unstructured":"Jack CR Jr., Knopman DS, Jagust WJ, Petersen RC, Weiner MW, Aisen PS et al. Tracking pathophysiological processes in Alzheimer's disease: an updated hypothetical model of dynamic biomarkers. Lancet Neurol 2013; 12: 207\u2013216.","journal-title":"Lancet Neurol"},{"key":"BFtp2016194_CR4","doi-asserted-by":"publisher","first-page":"263","DOI":"10.1016\/j.jalz.2011.03.005","volume":"7","author":"GM McKhann","year":"2011","unstructured":"McKhann GM, Knopman DS, Chertkow H, Hyman BT, Jack CR Jr., Kawas CH et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement 2011; 7: 263\u2013269.","journal-title":"Alzheimers Dement"},{"key":"BFtp2016194_CR5","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1002\/ana.21610","volume":"65","author":"LM Shaw","year":"2009","unstructured":"Shaw LM, Vanderstichele H, Knapik-Czajka M, Clark CM, Aisen PS, Petersen RC et al. Cerebrospinal fluid biomarker signature in Alzheimer's disease neuroimaging initiative subjects. Ann Neurol 2009; 65: 403\u2013413.","journal-title":"Ann Neurol"},{"key":"BFtp2016194_CR6","doi-asserted-by":"publisher","first-page":"455","DOI":"10.2217\/bmm.12.42","volume":"6","author":"AM Fagan","year":"2012","unstructured":"Fagan AM, Perrin RJ . Upcoming candidate cerebrospinal fluid biomarkers of Alzheimer's disease. Biomark Med 2012; 6: 455\u2013476.","journal-title":"Biomark Med"},{"issue":"Pt 3","key":"BFtp2016194_CR7","doi-asserted-by":"publisher","first-page":"844","DOI":"10.1093\/brain\/aws327","volume":"136","author":"M Lehmann","year":"2013","unstructured":"Lehmann M, Ghosh PM, Madison C, Laforce R Jr., Corbetta-Rastelli C, Weiner MW et al. Diverging patterns of amyloid deposition and hypometabolism in clinical variants of probable Alzheimer's disease. Brain 2013; 136 (Pt 3): 844\u2013858.","journal-title":"Brain"},{"key":"BFtp2016194_CR8","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1001\/jamaneurol.2015.1285","volume":"72","author":"CL Sutphen","year":"2015","unstructured":"Sutphen CL, Jasielec MS, Shah AR, Macy EM, Xiong CJ, Vlassenko AG et al. Longitudinal cerebrospinal fluid biomarker changes in preclinical alzheimer disease during middle age. JAMA Neurol 2015; 72: 1029\u20131042.","journal-title":"JAMA Neurol"},{"key":"BFtp2016194_CR9","doi-asserted-by":"publisher","first-page":"371","DOI":"10.1016\/j.jprot.2010.11.010","volume":"74","author":"AC Kroksveen","year":"2011","unstructured":"Kroksveen AC, Opsahl JA, Aye TT, Ulvik RJ, Berven FS . Proteomics of human cerebrospinal fluid: discovery and verification of biomarker candidates in neurodegenerative diseases using quantitative proteomics. J Proteomics 2011; 74: 371\u2013388.","journal-title":"J Proteomics"},{"key":"BFtp2016194_CR10","doi-asserted-by":"publisher","first-page":"769","DOI":"10.1016\/j.bbapap.2015.01.009","volume":"1854","author":"A Brinkmalm","year":"2015","unstructured":"Brinkmalm A, Portelius E, Ohrfelt A, Brinkmalm G, Andreasson U, Gobom J et al. Explorative and targeted neuroproteomics in Alzheimer's disease. Biochim Biophys Acta 2015; 1854: 769\u2013778.","journal-title":"Biochim Biophys Acta"},{"key":"BFtp2016194_CR11","doi-asserted-by":"publisher","first-page":"e64314","DOI":"10.1371\/journal.pone.0064314","volume":"8","author":"RJ Perrin","year":"2013","unstructured":"Perrin RJ, Payton JE, Malone JP, Gilmore P, Davis AE, Xiong C et al. Quantitative label-free proteomics for discovery of biomarkers in cerebrospinal fluid: assessment of technical and inter-individual variation. PLoS One 2013; 8: e64314.","journal-title":"PLoS One"},{"key":"BFtp2016194_CR12","doi-asserted-by":"publisher","first-page":"544","DOI":"10.1074\/mcp.M114.040576","volume":"14","author":"M Shi","year":"2015","unstructured":"Shi M, Movius J, Dator R, Aro P, Zhao Y, Pan C et al. Cerebrospinal fluid peptides as potential Parkinson disease biomarkers: a staged pipeline for discovery and validation. Mol Cell Proteomics 2015; 14: 544\u2013555.","journal-title":"Mol Cell Proteomics"},{"key":"BFtp2016194_CR13","first-page":"10","volume":"1","author":"WEGD Heywood","year":"2015","unstructured":"Heywood WE GD, Galimberti D, Bliss E, Sirka E, Paterson RW, Magdalinou N et al. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Mol Neurodegener 2015; 1: 10.","journal-title":"Mol Neurodegener"},{"key":"BFtp2016194_CR14","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1186\/1750-1326-9-22","volume":"9","author":"KR Wildsmith","year":"2014","unstructured":"Wildsmith KR, Schauer SP, Smith AM, Arnott D, Zhu Y, Haznedar J et al. Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics. Mol Neurodegener 2014; 9: 22.","journal-title":"Mol Neurodegener"},{"key":"BFtp2016194_CR15","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1038\/nmeth.2285","volume":"10","author":"V Marx","year":"2013","unstructured":"Marx V . Targeted proteomics. Nat Methods 2013; 10: 19\u201322.","journal-title":"Nat Methods"},{"key":"BFtp2016194_CR16","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1038\/nbt.1546","volume":"27","author":"TA Addona","year":"2009","unstructured":"Addona TA, Abbatiello SE, Schilling B, Skates SJ, Mani DR, Bunk DM et al. Multi-site assessment of the precision and reproducibility of multiple reaction monitoring-based measurements of proteins in plasma. Nat Biotechnol 2009; 27: 633\u2013641.","journal-title":"Nat Biotechnol"},{"key":"BFtp2016194_CR17","doi-asserted-by":"publisher","first-page":"537","DOI":"10.3233\/JAD-2011-101878","volume":"24","author":"P Johansson","year":"2011","unstructured":"Johansson P, Mattsson N, Hansson O, Wallin A, Johansson JO, Andreasson U et al. Cerebrospinal fluid biomarkers for Alzheimer's disease: diagnostic performance in a homogeneous mono-center population. J Alzheimers Dis 2011; 24: 537\u2013546.","journal-title":"J Alzheimers Dis"},{"key":"BFtp2016194_CR18","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1016\/j.jalz.2013.05.397","volume":"9","author":"SB Sylvain Lehmann","year":"2013","unstructured":"Sylvain Lehmann SB, Jerome N, Schraen-Maschke V, Tiers S, Delaby S, Becher C et al. Quantitative mass spectrometry (SRM\/MRM) for amyloid peptides, tau protein and apolipoprotein E in human cerebrospinal fluid for Alzheimer's disease diagnosis. Alzheimers Dement 2013; 9: 212.","journal-title":"Alzheimers Dement"},{"key":"BFtp2016194_CR19","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.jalz.2013.12.023","volume":"10","author":"FH Duits","year":"2014","unstructured":"Duits FH, Teunissen CE, Bouwman FH, Visser PJ, Mattsson N, Zetterberg H et al. The cerebrospinal fluid \"Alzheimer profile\": easily said, but what does it mean? Alzheimers Dement 2014; 10: 713\u201323 e2.","journal-title":"Alzheimers Dement"},{"key":"BFtp2016194_CR20","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1515\/CCLM.2006.258","volume":"44","author":"H Vanderstichele","year":"2006","unstructured":"Vanderstichele H, De Vreese K, Blennow K, Andreasen N, Sindic C, Ivanoiu A et al. Analytical performance and clinical utility of the INNOTEST PHOSPHO-TAU181P assay for discrimination between Alzheimer's disease and dementia with Lewy bodies. Clin Chem Lab Med 2006; 44: 1472\u20131480.","journal-title":"Clin Chem Lab Med"},{"key":"BFtp2016194_CR21","doi-asserted-by":"publisher","first-page":"3248","DOI":"10.1016\/j.jprot.2012.03.037","volume":"75","author":"W Heywood","year":"2012","unstructured":"Heywood W, Wang D, Madgett TE, Avent ND, Eaton S, Chitty LS et al. The development of a peptide SRM-based tandem mass spectrometry assay for prenatal screening of Down syndrome. J Proteomics 2012; 75: 3248\u20133257.","journal-title":"J Proteomics"},{"key":"BFtp2016194_CR22","doi-asserted-by":"publisher","first-page":"2013","DOI":"10.1021\/pr301200e","volume":"12","author":"V Manwaring","year":"2013","unstructured":"Manwaring V, Heywood WE, Clayton R, Lachmann RH, Keutzer J, Hindmarsh P et al. The identification of new biomarkers for identifying and monitoring kidney disease and their translation into a rapid mass spectrometry-based test: evidence of presymptomatic kidney disease in pediatric Fabry and type-I diabetic patients. J Proteome Res 2013; 12: 2013\u20132021.","journal-title":"J Proteome Res"},{"key":"BFtp2016194_CR23","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1186\/s13024-015-0059-y","volume":"10","author":"WE Heywood","year":"2015","unstructured":"Heywood WE, Galimberti D, Bliss E, Sirka E, Paterson RW, Magdalinou NK et al. Identification of novel CSF biomarkers for neurodegeneration and their validation by a high-throughput multiplexed targeted proteomic assay. Mol Neurodegener 2015; 10: 64.","journal-title":"Mol Neurodegener"},{"key":"BFtp2016194_CR24","doi-asserted-by":"publisher","first-page":"464","DOI":"10.1016\/j.ymeth.2012.02.004","volume":"56","author":"U Andreasson","year":"2012","unstructured":"Andreasson U, Portelius E, Pannee J, Zetterberg H, Blennow K . Multiplexing and multivariate analysis in neurodegeneration. Methods 2012; 56: 464\u2013470.","journal-title":"Methods"},{"key":"BFtp2016194_CR25","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1111\/j.1749-6632.1999.tb07819.x","volume":"893","author":"GE Gibson","year":"1999","unstructured":"Gibson GE, Park LCH, Zhang H, Sorbi S, Calingasan NY . Oxidative stress and a key metabolic enzyme in Alzheimer brains, cultured cells, and an animal model of chronic oxidative deficits. Ann N Y Acad Sci 1999; 893: 79\u201394.","journal-title":"Ann N Y Acad Sci"},{"key":"BFtp2016194_CR26","doi-asserted-by":"publisher","first-page":"11138","DOI":"10.1038\/srep11138","volume":"5","author":"JH Kim","year":"2015","unstructured":"Kim JH, Franck J, Kang T, Heinsen H, Ravid R, Ferrer I et al. Proteome-wide characterization of signalling interactions in the hippocampal CA4\/DG subfield of patients with Alzheimer's disease. Sci Rep 2015; 5: 11138.","journal-title":"Sci Rep"},{"key":"BFtp2016194_CR27","doi-asserted-by":"publisher","first-page":"695","DOI":"10.1002\/ana.20474","volume":"57","author":"P Bubber","year":"2005","unstructured":"Bubber P, Haroutunian V, Fisch G, Blass JP, Gibson GE . Mitochondrial abnormalities in Alzheimer brain: mechanistic implications. Ann Neurol 2005; 57: 695\u2013703.","journal-title":"Ann Neurol"},{"key":"BFtp2016194_CR28","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1111\/j.1532-5415.1976.tb03247.x","volume":"24","author":"od Velde","year":"1976","unstructured":"Velde od . Some cerebral proteins and enzyme systems in alzheimer's presenile and senile dementia. J Am Geriatr Soc 1976; 24: 12\u201316.","journal-title":"J Am Geriatr Soc"},{"key":"BFtp2016194_CR29","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/0197-4580(86)90022-9","volume":"7","author":"S Hoyer","year":"1986","unstructured":"Hoyer S, Krier C . Ischemia and aging brain. Studies on glucose and energy metabolism in rat cerebral cortex. Neurobiol Aging 1986; 7: 23\u201329.","journal-title":"Neurobiol Aging"},{"key":"BFtp2016194_CR30","doi-asserted-by":"publisher","first-page":"568","DOI":"10.1007\/s11682-012-9208-x","volume":"6","author":"C Habeck","year":"2012","unstructured":"Habeck C, Risacher S, Lee GJ, Glymour MM, Mormino E, Mukherjee S et al. Relationship between baseline brain metabolism measured using [(1)(8)F]FDG PET and memory and executive function in prodromal and early Alzheimer's disease. Brain Imaging Behav 2012; 6: 568\u2013583.","journal-title":"Brain Imaging Behav"},{"key":"BFtp2016194_CR31","doi-asserted-by":"publisher","first-page":"79","DOI":"10.3389\/fnmol.2012.00079","volume":"5","author":"G Kaur","year":"2012","unstructured":"Kaur G, Levy E . Cystatin C in Alzheimer's disease. Front Mol Neurosci 2012; 5: 79.","journal-title":"Front Mol Neurosci"},{"key":"BFtp2016194_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pone.0016032","volume":"6","author":"RJ Perrin","year":"2011","unstructured":"Perrin RJ, Craig-Schapiro R, Malone JP, Shah AR, Gilmore P, Davis AE et al. Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease. PLoS One 2011; 6: 1.","journal-title":"PLoS One"},{"key":"BFtp2016194_CR33","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1016\/j.neurobiolaging.2007.06.009","volume":"30","author":"O Hansson","year":"2009","unstructured":"Hansson O, Buchhave P, Zetterberg H, Blennow K, Minthon L, Warkentin S . Combined rCBF and CSF biomarkers predict progression from mild cognitive impairment to Alzheimer's disease. Neurobiol Aging 2009; 30: 165\u2013173.","journal-title":"Neurobiol Aging"},{"key":"BFtp2016194_CR34","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1371\/journal.pone.0018850","volume":"6","author":"R Craig-Schapiro","year":"2011","unstructured":"Craig-Schapiro R, Kuhn M, Xiong CJ, Pickering EH, Liu JX, Misko TP et al. Multiplexed immunoassay panel identifies novel CSF biomarkers for Alzheimer's disease diagnosis and prognosis. PLoS One 2011; 6: 4.","journal-title":"PLoS One"},{"key":"BFtp2016194_CR35","doi-asserted-by":"publisher","first-page":"1486","DOI":"10.1002\/pmic.200300470","volume":"3","author":"O Carrette","year":"2003","unstructured":"Carrette O, Demalte I, Scherl A, Yalkinoglu O, Corthals G, Burkhard P et al. A panel of cerebrospinal fluid potential biomarkers for the diagnosis of Alzheimer's disease. Proteomics 2003; 3: 1486\u20131494.","journal-title":"Proteomics"},{"key":"BFtp2016194_CR36","doi-asserted-by":"publisher","first-page":"2000","DOI":"10.1074\/mcp.M500207-MCP200","volume":"4","author":"Y Hu","year":"2005","unstructured":"Hu Y, Malone JP, Fagan AM, Townsend RR, Holtzman DM . Comparative proteomic analysis of intra- and interindividual variation in human cerebrospinal fluid. Mol Cell Proteomics 2005; 4: 2000\u20132009.","journal-title":"Mol Cell Proteomics"},{"key":"BFtp2016194_CR37","doi-asserted-by":"publisher","first-page":"e419","DOI":"10.1038\/tp.2014.58","volume":"4","author":"RW Paterson","year":"2014","unstructured":"Paterson RW, Bartlett JW, Blennow K, Fox NC, Alzheimer's Disease Neuroimaging I, Shaw LM et al. Cerebrospinal fluid markers including trefoil factor 3 are associated with neurodegeneration in amyloid-positive individuals. Transl Psychiatry 2014; 4: e419.","journal-title":"Transl Psychiatry"},{"key":"BFtp2016194_CR38","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2174\/156720507779939869","volume":"4","author":"JK Wung","year":"2007","unstructured":"Wung JK, Perry G, Kowalski A, Harris PL, Bishop GM, Trivedi MA et al. Increased expression of the remodeling- and tumorigenic-associated factor osteopontin in pyramidal neurons of the Alzheimer's disease brain. Curr Alzheimer Res 2007; 4: 67\u201372.","journal-title":"Curr Alzheimer Res"},{"key":"BFtp2016194_CR39","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.neurobiolaging.2008.06.011","volume":"31","author":"O Wirths","year":"2010","unstructured":"Wirths O, Breyhan H, Marcello A, Cotel MC, Bruck W, Bayer TA . Inflammatory changes are tightly associated with neurodegeneration in the brain and spinal cord of the APP\/PS1KI mouse model of Alzheimer's disease. Neurobiol Aging 2010; 31: 747\u2013757.","journal-title":"Neurobiol Aging"},{"key":"BFtp2016194_CR40","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.3233\/JAD-2010-1309","volume":"19","author":"C Comi","year":"2010","unstructured":"Comi C, Carecchio M, Chiocchetti A, Nicola S, Galimberti D, Fenoglio C et al. Osteopontin is increased in the cerebrospinal fluid of patients with Alzheimer's disease and its levels correlate with cognitive decline. J Alzheimers Dis 2010; 19: 1143\u20131148.","journal-title":"J Alzheimers Dis"},{"key":"BFtp2016194_CR41","doi-asserted-by":"publisher","first-page":"615745","DOI":"10.1155\/2013\/615745","volume":"2013","author":"Y Sun","year":"2013","unstructured":"Sun Y, Yin XS, Guo H, Han RK, He RD, Chi LJ . Elevated osteopontin levels in mild cognitive impairment and Alzheimer's disease. Mediators Inflammation 2013; 2013: 615745.","journal-title":"Mediators Inflammation"},{"key":"BFtp2016194_CR42","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1001\/archneurol.2011.642","volume":"69","author":"JM Ringman","year":"2012","unstructured":"Ringman JM, Schulman H, Becker C, Jones T, Bai Y, Immermann F et al. Proteomic changes in cerebrospinal fluid of presymptomatic and affected persons carrying familial Alzheimer disease mutations. Arch Neurol 2012; 69: 96\u2013104.","journal-title":"Arch Neurol"},{"key":"BFtp2016194_CR43","doi-asserted-by":"publisher","first-page":"e0134368","DOI":"10.1371\/journal.pone.0134368","volume":"10","author":"W Khan","year":"2015","unstructured":"Khan W, Aguilar C, Kiddle SJ, Doyle O, Thambisetty M, Muehlboeck S et al. A subset of cerebrospinal fluid proteins from a multi-analyte panel associated with brain atrophy, disease classification and prediction in Alzheimer's disease. PLoS One 2015; 10: e0134368.","journal-title":"PLoS One"},{"key":"BFtp2016194_CR44","doi-asserted-by":"publisher","first-page":"715","DOI":"10.1002\/prca.201400178","volume":"9","author":"DS Spellman","year":"2015","unstructured":"Spellman DS, Wildsmith KR, Honigberg LA, Tuefferd M, Baker D, Raghavan N et al. Development and evaluation of a multiplexed mass spectrometry based assay for measuring candidate peptide biomarkers in Alzheimer's Disease Neuroimaging Initiative (ADNI) CSF. Proteomics Clin Appl 2015; 9: 715\u2013731.","journal-title":"Proteomics Clin Appl"},{"key":"BFtp2016194_CR45","doi-asserted-by":"publisher","first-page":"901","DOI":"10.3233\/JAD-140624","volume":"42","author":"A Antonell","year":"2014","unstructured":"Antonell A, Mansilla A, Rami L, Llado A, Iranzo A, Olives J et al. Cerebrospinal fluid level of YKL-40 protein in preclinical and prodromal Alzheimer's disease. J Alzheimers Dis 2014; 42: 901\u2013908.","journal-title":"J Alzheimers Dis"},{"key":"BFtp2016194_CR46","doi-asserted-by":"publisher","first-page":"903","DOI":"10.1016\/j.biopsych.2010.08.025","volume":"68","author":"R Craig-Schapiro","year":"2010","unstructured":"Craig-Schapiro R, Perrin RJ, Roe CM, Xiong C, Carter D, Cairns NJ et al. YKL-40: a novel prognostic fluid biomarker for preclinical Alzheimer's disease. Biol Psychiatry 2010; 68: 903\u2013912.","journal-title":"Biol Psychiatry"},{"key":"BFtp2016194_CR47","doi-asserted-by":"publisher","first-page":"59","DOI":"10.1186\/s13195-015-0142-1","volume":"7","author":"MI Kester","year":"2015","unstructured":"Kester MI, Teunissen CE, Sutphen C, Herries EM, Ladenson JH, Xiong C et al. Cerebrospinal fluid VILIP-1 and YKL-40, candidate biomarkers to diagnose, predict and monitor Alzheimer's disease in a memory clinic cohort. Alzheimers Res Ther 2015; 7: 59.","journal-title":"Alzheimers Res Ther"},{"key":"BFtp2016194_CR48","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/j.euprot.2015.07.012","volume":"8","author":"M Rezeli","year":"2015","unstructured":"Rezeli M, Zetterberg H, Blennow K, Brinkmalm A, Laurell T, Hansson O et al. Quantification of total apolipoprotein E and its specific isoforms in cerebrospinal fluid and blood in Alzheimer\u2019s disease and other neurodegenerative diseases. EuPA Open Proteomics 2015; 8: 137\u2013143.","journal-title":"EuPA Open Proteomics"},{"key":"BFtp2016194_CR49","doi-asserted-by":"publisher","first-page":"633","DOI":"10.1007\/s00401-014-1266-2","volume":"127","author":"E Martinez-Morillo","year":"2014","unstructured":"Martinez-Morillo E, Hansson O, Atagi Y, Bu G, Minthon L, Diamandis EP et al. Total apolipoprotein E levels and specific isoform composition in cerebrospinal fluid and plasma from Alzheimer's disease patients and controls. Acta Neuropathol 2014; 127: 633\u2013643.","journal-title":"Acta Neuropathol"},{"key":"BFtp2016194_CR50","doi-asserted-by":"publisher","first-page":"1240","DOI":"10.1136\/jnnp-2014-309562","volume":"86","author":"NK Magdalinou","year":"2015","unstructured":"Magdalinou NK, Paterson RW, Schott JM, Fox NC, Mummery C, Blennow K et al. A panel of nine cerebrospinal fluid biomarkers may identify patients with atypical parkinsonian syndromes. J Neurol Neurosurg Psychiatry 2015; 86: 1240\u20131247.","journal-title":"J Neurol Neurosurg Psychiatry"},{"key":"BFtp2016194_CR51","doi-asserted-by":"publisher","first-page":"041805","DOI":"10.1103\/PhysRevLett.108.041805","volume":"108","author":"G Aad","year":"2012","unstructured":"Aad G, Abbott B, Abdallah J, Abdelalim AA, Abdesselam A, Abdinov O et al. Search for new phenomena in tt events with large missing transverse momentum in proton-proton collisions at sqrt[s] = 7 TeV with the ATLAS detector. Phys Rev Lett 2012; 108: 041805.","journal-title":"Phys Rev Lett"},{"key":"BFtp2016194_CR52","doi-asserted-by":"publisher","first-page":"480","DOI":"10.1002\/ana.20425","volume":"57","author":"DS Knopman","year":"2005","unstructured":"Knopman DS, Boeve BF, Parisi JE, Dickson DW, Smith GE, Ivnik RJ et al. Antemortem diagnosis of frontotemporal lobar degeneration. Ann Neurol 2005; 57: 480\u2013488.","journal-title":"Ann Neurol"},{"issue":"Pt 9","key":"BFtp2016194_CR53","doi-asserted-by":"publisher","first-page":"2478","DOI":"10.1093\/brain\/awr189","volume":"134","author":"JS Snowden","year":"2011","unstructured":"Snowden JS, Thompson JC, Stopford CL, Richardson AM, Gerhard A, Neary D et al. The clinical diagnosis of early-onset dementias: diagnostic accuracy and clinicopathological relationships. Brain 2011; 134 (Pt 9): 2478\u20132492.","journal-title":"Brain"},{"issue":"Pt 10","key":"BFtp2016194_CR54","doi-asserted-by":"publisher","first-page":"2636","DOI":"10.1093\/brain\/awm213","volume":"130","author":"S Alladi","year":"2007","unstructured":"Alladi S, Xuereb J, Bak T, Nestor P, Knibb J, Patterson K et al. Focal cortical presentations of Alzheimer's disease. Brain 2007; 130 (Pt 10): 2636\u20132645.","journal-title":"Brain"},{"key":"BFtp2016194_CR55","doi-asserted-by":"publisher","first-page":"952","DOI":"10.1002\/ana.20873","volume":"59","author":"MS Forman","year":"2006","unstructured":"Forman MS, Farmer J, Johnson JK, Clark CM, Arnold SE, Coslett HB et al. Frontotemporal dementia: clinicopathological correlations. Ann Neurol 2006; 59: 952\u2013962.","journal-title":"Ann Neurol"},{"key":"BFtp2016194_CR56","first-page":"919","volume":"51","author":"S Lehmann","year":"2013","unstructured":"Lehmann S, Hoofnagle A, Hochstrasser D, Brede C, Glueckmann M, Cocho JA et al. Quantitative Clinical Chemistry Proteomics (qCCP) using mass spectrometry: general characteristics and application. Clin Chem Lab Med 2013; 51: 919\u2013935.","journal-title":"Clin Chem Lab Med"},{"key":"BFtp2016194_CR57","doi-asserted-by":"publisher","first-page":"1796","DOI":"10.1373\/clinchem.2008.109652","volume":"54","author":"AN Hoofnagle","year":"2008","unstructured":"Hoofnagle AN, Becker JO, Wener MH, Heinecke JW . Quantification of thyroglobulin, a low-abundance serum protein, by immunoaffinity peptide enrichment and tandem mass spectrometry. Clin Chem 2008; 54: 1796\u20131804.","journal-title":"Clin Chem"},{"key":"BFtp2016194_CR58","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1016\/j.jchromb.2013.05.003","volume":"930","author":"YS Choi","year":"2013","unstructured":"Choi YS, Hou S, Choe LH, Lee KH . Targeted human cerebrospinal fluid proteomics for the validation of multiple Alzheimer's disease biomarker candidates. J Chromatogr B 2013; 930: 129\u2013135.","journal-title":"J Chromatogr B"},{"key":"BFtp2016194_CR59","doi-asserted-by":"publisher","first-page":"5996","DOI":"10.1021\/pr400877e","volume":"12","author":"D Lin","year":"2013","unstructured":"Lin D, Alborn WE, Slebos RJ, Liebler DC . Comparison of protein immunoprecipitation-multiple reaction monitoring with ELISA for assay of biomarker candidates in plasma. J Proteome Res 2013; 12: 5996\u20136003.","journal-title":"J Proteome Res"},{"key":"BFtp2016194_CR60","doi-asserted-by":"publisher","first-page":"e584","DOI":"10.1038\/tp.2015.78","volume":"5","author":"SJ Kiddle","year":"2015","unstructured":"Kiddle SJ, Steves CJ, Mehta M, Simmons A, Xu X, Newhouse S et al. Plasma protein biomarkers of Alzheimer's disease endophenotypes in asymptomatic older twins: early cognitive decline and regional brain volumes. Transl Psychiatry 2015; 5: e584.","journal-title":"Transl Psychiatry"},{"key":"BFtp2016194_CR61","first-page":"5","volume":"32","author":"SK Grebe","year":"2011","unstructured":"Grebe SK, Singh RJ . LC-MS\/MS in the clinical laboratory - where to from here? Clin Biochem Rev 2011; 32: 5\u201331.","journal-title":"Clin Biochem Rev"},{"key":"BFtp2016194_CR62","doi-asserted-by":"publisher","first-page":"e38013","DOI":"10.1371\/journal.pone.0038013","volume":"7","author":"KR Wildsmith","year":"2012","unstructured":"Wildsmith KR, Basak JM, Patterson BW, Pyatkivskyy Y, Kim J, Yarasheski KE et al. In vivo human apolipoprotein E isoform fractional turnover rates in the CNS. PLoS One 2012; 7: e38013.","journal-title":"PLoS One"}],"container-title":["Translational Psychiatry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/tp2016194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tp2016194","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/tp2016194.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,4]],"date-time":"2023-01-04T08:54:45Z","timestamp":1672822485000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/tp2016194"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,11,15]]},"references-count":62,"journal-issue":{"issue":"11","published-online":{"date-parts":[[2016,11]]}},"alternative-id":["BFtp2016194"],"URL":"https:\/\/doi.org\/10.1038\/tp.2016.194","relation":{},"ISSN":["2158-3188"],"issn-type":[{"value":"2158-3188","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,11,15]]},"assertion":[{"value":"12 May 2016","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"31 July 2016","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 November 2016","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no conflict of interest.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}